• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[2型糖尿病降糖治疗指南(2023年更新版)]

[Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2023)].

作者信息

Clodi Martin, Abrahamian Heidemarie, Brath Helmut, Schernthaner Guntram, Brix Johann, Ludvik Bernhard, Drexel Heinz, Saely Christoph H, Fasching Peter, Rega-Kaun Gersina, Föger Bernhard, Francesconi Claudia, Fröhlich-Reiterer Elke, Kautzky-Willer Alexandra, Harreiter Jürgen, Luger Anton, Resl Michael, Riedl Michaela, Winhofer Yvonne, Hofer Sabine E, Hoppichler Friedrich, Huber Joakim, Kaser Susanne, Ress Claudia, Lechleitner Monika, Aberer Felix, Mader Julia K, Sourij Harald, Toplak Hermann, Paulweber Bernhard, Stechemesser Lars, Pieber Thomas, Prager Rudolf, Stingl Harald, Stulnig Thomas, Rami-Merhar Birgit, Drexel Heinz, Roden Michael, Schelkshorn Christian, Wascher Thomas C, Weitgasser Raimund, Zlamal-Fortunat Sandra

机构信息

ICMR - Institute for Cardiovascular and Metabolic Research, Johannes Kepler Universität Linz JKU Linz, Altenberger Straße 69, 4040, Linz, Österreich.

Abteilung für Innere Medizin mit Diabetologie, Gastroenterologie und Hepatologie, Rheumatologie und Intensivmedizin, , Konventhospital der Barmherzigen Brüder Linz, Linz, Österreich.

出版信息

Wien Klin Wochenschr. 2023 Jan;135(Suppl 1):32-44. doi: 10.1007/s00508-023-02186-4. Epub 2023 Apr 20.

DOI:10.1007/s00508-023-02186-4
PMID:37101023
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10133357/
Abstract

Hyperglycemia significantly contributes to complications in patients with diabetes mellitus. While lifestyle interventions remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. The definition of individual targets regarding optimal therapeutic efficacy and safety as well as cardiovascular effects is of great importance. In this guideline we present the most current evidence-based best clinical practice data for healthcare professionals.

摘要

高血糖显著导致糖尿病患者出现并发症。虽然生活方式干预仍然是疾病预防和治疗的基石,但大多数2型糖尿病患者最终仍需要药物治疗来控制血糖。确定关于最佳治疗效果、安全性以及心血管效应的个体目标至关重要。在本指南中,我们为医疗保健专业人员提供了最新的循证最佳临床实践数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3ef/10133357/21613e9de102/508_2023_2186_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3ef/10133357/21613e9de102/508_2023_2186_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3ef/10133357/21613e9de102/508_2023_2186_Fig1_HTML.jpg

相似文献

1
[Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2023)].[2型糖尿病降糖治疗指南(2023年更新版)]
Wien Klin Wochenschr. 2023 Jan;135(Suppl 1):32-44. doi: 10.1007/s00508-023-02186-4. Epub 2023 Apr 20.
2
[Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2019)].《2型糖尿病降糖治疗指南(2019年更新版)》
Wien Klin Wochenschr. 2019 May;131(Suppl 1):27-38. doi: 10.1007/s00508-019-1471-z.
3
[Antihyperglycemic treatment guidelines for diabetes mellitus type 2].[2型糖尿病降糖治疗指南]
Wien Klin Wochenschr. 2016 Apr;128 Suppl 2:S45-53. doi: 10.1007/s00508-016-0991-z.
4
[Antihyperglycemic Treatment Guidelines for diabetes mellitus type 2].[2型糖尿病抗高血糖治疗指南]
Wien Klin Wochenschr. 2012 Dec;124 Suppl 2:10-6. doi: 10.1007/s00508-012-0263-5.
5
Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus.现行 2 型糖尿病患者抗高血糖治疗指南和算法。
Am J Med. 2010 Mar;123(3 Suppl):S12-8. doi: 10.1016/j.amjmed.2009.12.005.
6
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.2型糖尿病的药物治疗:现有疗法
Am J Med. 2017 Jun;130(6S):S4-S17. doi: 10.1016/j.amjmed.2017.04.004.
7
Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs.心血管疾病与2型糖尿病:血糖调节与调节药物
Curr Cardiol Rep. 2009 Jul;11(4):258-63. doi: 10.1007/s11886-009-0038-4.
8
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.2型糖尿病的药物治疗:现有疗法
Am J Cardiol. 2017 Jul 1;120(1S):S4-S16. doi: 10.1016/j.amjcard.2017.05.009. Epub 2017 May 30.
9
So Many Antihyperglycemics: How to Choose? A Practical Approach.如此多的抗高血糖药物:如何选择?一种实用方法。
Can J Diabetes. 2017 Oct;41(5):469-473. doi: 10.1016/j.jcjd.2017.04.001. Epub 2017 Jun 7.
10
Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.新型降糖药物对 2 型糖尿病患者体重的影响。
Can J Diabetes. 2015 Dec;39 Suppl 5:S148-54. doi: 10.1016/j.jcjd.2015.09.090.

引用本文的文献

1
Intrahospital Prevalence of Diabetes and Prediabetes in Medical Departments in Upper Austria.奥地利上奥地利州各医疗科室糖尿病及糖尿病前期的院内患病率
J Clin Med. 2025 May 23;14(11):3668. doi: 10.3390/jcm14113668.
2
Systematic review of guideline recommendations for older and frail adults with type 2 diabetes mellitus.2 型糖尿病老年体弱患者指南推荐的系统评价。
Age Ageing. 2024 Nov 1;53(11). doi: 10.1093/ageing/afae259.

本文引用的文献

1
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.达格列净治疗射血分数轻度降低或保留的心力衰竭。
N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27.
2
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
3
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
每周一次替西帕肽与每日一次德谷胰岛素联用,或不联用 SGLT2 抑制剂,作为二甲双胍的附加疗法治疗 2 型糖尿病患者(SURPASS-3):一项随机、开放标签、平行分组、3 期临床试验。
Lancet. 2021 Aug 14;398(10300):583-598. doi: 10.1016/S0140-6736(21)01443-4. Epub 2021 Aug 6.
4
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.索格列净治疗伴有近期恶化心力衰竭的糖尿病患者。
N Engl J Med. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16.
5
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.索格列净在伴有慢性肾脏病的糖尿病患者中的应用。
N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186. Epub 2020 Nov 16.
6
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
7
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.在 2 型糖尿病患者中使用依格列净的心血管结局。
N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23.
8
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
9
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.达格列净治疗射血分数降低的心力衰竭患者。
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
10
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.度拉糖肽与 2 型糖尿病患者的心血管结局(REWIND):一项双盲、随机、安慰剂对照试验。
Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.